Pear Therapeutics, Inc. ( PEAR) Stock. Should you Buy or Sell? $ 1.94
0.24 (11.01 %)
Pear Therapeutics, Inc. Analysis
Updated on 10-09-2022| Symbol | PEAR |
| Price | $1.94 |
| Beta | 0.000 |
| Volume Avg. | $271.24 thousand |
| Market Cap | $269.21 M |
| 52 Week Range | $1.34 - $14.6 |
Pear Therapeutics, Inc. opened the day at $1.94 which is +'11.01 % on yesterday's close. Pear Therapeutics, Inc. has a 52 week high of $14.6 and 52 week low of $1.34, which is a difference of $13.26. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $269.21 M and total net profit is $4208000 which means the company is trading at 63.98 times profit to market capitalization. Theoretically, if you were to buy Pear Therapeutics, Inc. for $269.21 M, it would take 15 years to get your money back. Pear Therapeutics, Inc. are in the Health Information Services space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
Pear Therapeutics, Inc. Stock Forecast - Is Pear Therapeutics, Inc. a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Neutral | |
| ROA Score | Neutral | |
| DE Score | Buy | |
| PE Score | Strong Buy | |
| PB Score | Strong Buy | |
| Overall Recommendation | Strong Buy |
Growth and Value
| PE Ratio | -3.211 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | -8.147 |
Valuing Pear Therapeutics, Inc.
| Price Book Value Ratio | 3.394 | Price To Book Ratio | 3.394 |
| Price To Sales Ratio | 26.163 | Price Earnings Ratio | -3.211 |
How liquid is Pear Therapeutics, Inc.
| Current Ratio | 2.574 |
| Quick Ratio | 2.395 |
Debt
| Debt Ratio | 0.445 | Debt Equity Ratio | 0.803 |
| Long Term Debt To Capitalization | 0.104 | Total Debt To Capitalization | 0.123 |
Latest news about Pear Therapeutics, Inc.
Lots of payors are adding reSET to their covered benefit plans, and savings results far exceed prices of the products, usually leaving about 50% in surplus for the health system. Payor contract economics is making timing issues for revenue recognition, but run-rate revenue still indicates Pear is still annualising $12 million in revenue.
Pear Therapeutics, Inc. (NASDAQ:PEAR ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Meara Murphy - Senior Director of Corporate Communications Ronan O'Brien - General Counsel and Chief Compliance Officer Corey McCann - President and Chief Executive Officer Chris Guiffre - Chief Financial Officer and Chief Operating Officer Yuri Maricich - Chief Medical Officer Julia Strandberg - Chief Commercial Officer Conference Call Participants Judah Frommer - Credit Suisse Michael Cherny - Bank of America Neena Garg - Citi Eric Percher - Nephron Research Rahul Rakhit - LifeSci Capital Keay Nakae - Chardan Marie Thibault - BTIG Operator Good afternoon, everyone. Welcome to the Pear Therapeutics Second Quarter 2022 Earnings Conference Call.
Pear Therapeutics (PEAR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Penny stocks with unusual options activity today. The post Penny Stocks To Buy Now?
Fulfilment rates are growing relative to last quarter, and so are prescriptions. Government traction is becoming more evident as states mandate coverage of Pear products for all resident Medicaid members, and payment rates should rise on account of that.
About Pear Therapeutics, Inc.
Description :
Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.
